The Reflection of Quality
An integrated healthcare system, built through science, disciplined processes, and trusted delivery.
For further information on partnership and business opportunities, please contact: info@dexagroup.com
Insights & Perspectives
20 February 2026
From Quality to Public Trust
In the healthcare industry, public trust is not built overnight. It grows through consistent quality assurance, adherence to standards, and contributions that are tangibly felt by society. As demands for transparency continue to rise, healthcare companies are expected not only to deliver good products, but also to establish accurate and responsible communication. For more than five decades, Dexa Group has embraced the philosophy Expertise for the Promotion of Health as the foundation for...
3 February 2026
Dexa Medica Receives the 2026 BPOM Achievement Award as Indonesia’s Leading Phytopharmaceutical Company
Dexa Medica has once again affirmed its role as a pioneer in Indonesia’s pharmaceutical industry through an award presented by the National Agency of Drug and Food Control (BPOM) of the Republic of Indonesia. The BPOM Achievement Award 2026 in the category of Pioneer with the Highest Number of Phytopharmaceutical Products in Indonesia was presented by the Head of BPOM RI, Prof. Dr. Taruna Ikrar, to the President Director of PT Dexa Medica, Mr. V. Hery Sutanto. The award ceremony took place...
30 December 2025
Right to Win Through Visionary Leadership: Dexa Group Wins the Indonesia CEO Excellence Award 2025
Dexa Group has once again achieved a strategic milestone by receiving the Indonesia CEO Excellence Award 2025, organized by WartaEkonomi.co.id Research and Consulting. This award recognizes visionary leadership that consistently drives business sustainability while strengthening the pharmaceutical sector’s contribution to national health resilience. The award was presented by Muhamad Ihsan, CEO & Chief Editor of WartaEkonomi.co.id, to Andy Samual, Director of Human Resources and General...
10 December 2025
Karya Anak Bangsa 2025 Award Presented to Dexa Medica for Strategic Contribution to Advancing Indonesia’s Health Innovation
On the occasion of the 61st National Health Day (HKN), Dexa Medica achieved a significant milestone by receiving the Karya Anak Bangsa Award from the Ministry of Health of the Republic of Indonesia, recognizing it as the pharmaceutical industry with the highest number of clinical trials for natural-based drugs in the country. The award was presented during the Health Innovation Festival (HAI-Fest) 2025 held at Kartika Expo Balai Kartini, Jakarta, on Monday, December 8, 2025. V. Hery Sutanto,...
25 November 2025
DLBS Brings Indonesia’s Biodiversity to the Global Pharmaceutical Stage at CPHI Frankfurt 2025
As global interest in herbal medicines continues to grow, only a limited number of products are developed with rigorous scientific methods and supported by strong clinical evidence. DLBS addresses this gap through the development of Integrative Modern Natural Medicines—therapeutics based on defined bioactive fractions with clear mechanisms of action and clinically validated efficacy (phytopharmaceuticals) in accordance with Good Clinical Practice. This commitment was showcased by DLBS at the...
- Page 1
Recognition
Dexa Group's commitment to delivering nationally and globally standardized quality is demonstrated through its tangible contributions to public health and the pharmaceutical industry. From developing research-based innovations and strengthening national healthcare independence to fulfilling therapeutic needs for millions of chronic disease patients and expanding products into international markets, Dexa continues to reinforce its role as a healthcare company that creates meaningful impact. This consistency has earned recognition and appreciation from regulatory authorities, government institutions, national media, and international organizations — reflecting Dexa's strong track record in quality, innovation, export leadership, integrity, and trusted corporate governance.
Certified Facilities
Dexa Medica
Palembang
Core legacy manufacturing — broad-volume pharmaceutical output.
Core Specializations:
Oral solid non-Cephalosporine (tablet, caplet, hard gelatin capsule, dry syrup) & Cephalosporine (tablet, hard gelatin capsule, dry syrup, dry powder injection).
Certifications:
Dexa Medica
Cikarang
API and specialty manufacturing; Industry 4.0 implementation hub.
Core Specializations:
Natural Extract Active Pharmaceutical Ingredients, Protein Extracts, Oral Solid Dosage Forms.
Certifications:
Ferron Par Pharmaceuticals
Cikarang
Regulated-market export platform — UK-MHRA certified oral solid facility.
Core Specializations:
Solids, liquids, semi-solids, sterile injectables, eye drops, API bulk lyo.
Certifications:
Beta Pharmacon
Karawang
High-volume, efficiency-oriented access manufacturing.
Core Specializations:
Tablets, soft capsule, soft-gels.
Certifications:
Fonko International Pharmaceuticals
Cikarang
Specialized oncology manufacturing — EU-GMP certified.
Core Specializations:
Oncology small volume injection, Oncology freeze dry injection, Oncology tablet, Oncology hard capsule.
Certifications:
Dexa Laboratories of Biomolecular Sciences (DLBS)
Cikarang
Integrative Natural-Modern Medicine (OMAI) Research Center — Including Stimuno® (Phytopharmaceutical) and HerbaKOF® (Standardized Herbal Medicine).
Core Specializations:
Research and Development of Integrative Natural-Modern Medicine (OMAI).
Certifications:
Anugrah Amartha Global
Bogor
OMAI & high-value product manufacturing platform.
Core Specializations:
Oral Solid Dosage Forms, Semi-Solid, Natural Oral Liquid, Natural Supplements and Softgels, and Bioactive Natural Fractions for API Development.
Certifications:
Dexa Development Center
Cikarang
The Dexa Development Center serves as the Dexa Group's innovation and new product development hub.
Core Specializations:
Focusing on first off-patent generics, complex generics (formulations, dosage forms, etc) and new drug delivery systems.
Certifications:
Public Trust Snapshot
Through the Dexa Quality Campaign Survey, thousands of respondents expressed strong confidence in Dexa Group. With an overall score of 4.92 out of 5, the result reflects that Dexa's quality is not only embedded in its products, but has become an integral part of the company's identity — built upon science, integrity, and global standards. From research and high-precision manufacturing processes to a safeguarded distribution system and recognition from both national and international regulatory bodies such as EU-GMP, Dexa Group consistently delivers trusted and reliable quality. This trust continues to live on among Indonesian families and serves as the foundation for Dexa's journey as a respected global healthcare company.
QUALITY RATING
4.92
FROM 5
Participants Demographic
33 Provinces
in Indonesia
End-to-end Quality Implementation
Research & Innovation
Dexa Group develops science-based healthcare innovations through the Dexa Development Center (DDC) and the Dexa Laboratories of Biomolecular Sciences (DLBS). Research activities span first off-patent generics, complex generics (formulations, dosage forms, and related developments), new drug delivery systems, and Integrative Modern Natural Medicines in the form of phytopharmaceuticals and standardized herbal medicines derived from Indonesia's biodiversity. Supported by multidisciplinary researchers and continuous R&D investment, Dexa Group transforms research into validated healthcare solutions relevant to international markets.
Globally Aligned Manufacturing
Dexa Group operates manufacturing facilities that comply with national and international standards, including EU-GMP, supported by modern technology and rigorous quality control systems. Selected facilities have obtained international certifications and regulatory recognitions, including from authorities in Indonesia, the United Kingdom, Qatar, Zimbabwe, Tanzania, Hungary, and Portugal. Each facility is designed to ensure precision, consistency, and reliability of quality across global markets.
Halal Integrity
Dexa Group's commitment to quality extends through halal integrity, maintained from raw material sourcing and production to distribution. This system ensures that products reaching patients and consumers meet halal standards applicable in Indonesia, while strengthening public trust in the healthcare solutions we deliver.
Integrated Distribution Network
Dexa Group maintains product accessibility through an integrated distribution system serving healthcare facilities, pharmacies, and institutional partners across Indonesia and export markets. The distribution network is designed to safeguard product integrity, availability, traceability, and delivery reliability, ensuring healthcare solutions reach patients with consistent quality throughout the supply chain.
Compliance & Quality Systems
Dexa Group implements an integrated Quality Management System (QMS) across all of its business units. The system is supported by quantitative assessments through quality metrics, operational KPIs, and Pharmaceutical Industry Maturity Assessments aligned with the standards of the Indonesian Food and Drug Authority (BPOM RI), as well as internally developed frameworks that refer to the Pharmaceutical Quality System (PQS) under ICH Q10 and the International Society for Pharmaceutical Engineering (ISPE) standards. Quality is embedded at every stage of the product lifecycle, from development and technology transfer to commercial manufacturing and post-marketing monitoring.
Our Commitment
Dexa Group operates an end-to-end quality system designed to ensure consistency, compliance, and reliability across the healthcare value chain. This commitment is reflected through science-based innovation, disciplined manufacturing processes, integrated distribution systems, compliance with national and international regulations, halal integrity, and continuous operational improvement. Through these systems, Dexa Group delivers healthcare solutions that remain trusted by healthcare professionals, institutions, and communities.
Quality Beyond Products
At Dexa Group, quality extends beyond the final product. It is built into every stage of the healthcare journey, from scientific discovery and product development to manufacturing systems, supply chain integrity, and patient access. This philosophy has shaped Dexa Group since its establishment in 1969 under one enduring principle: Quality Above All. Supported by continuous investment in research and development, integrated operational systems, and manufacturing standards aligned with international regulations, Dexa Group continues to strengthen its role as a trusted healthcare partner in Indonesia and global markets.
Since 1969, Dexa Group has built healthcare capabilities that connect research, manufacturing, distribution, and patient access into one integrated system. Across discovery, regulatory compliance, manufacturing precision, and nationwide distribution, every process is designed to ensure consistency, reliability, and long-term trust. The principle of "Quality Above All" guides these capabilities across Indonesia and international markets.